RecruitingNot ApplicableNCT07071441

Indomethacin vs Diclofenac for Preventing PEP

Rectal Indomethacin Versus Diclofenac for Prevention of Post-ERCP Panceratitis (IDPPP2): A Multicenter, Double-blind, Randomized, Control Trial


Sponsor

Air Force Military Medical University, China

Enrollment

4,050 participants

Start Date

Jun 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare expenses. Preprocedural administration of rectal non-steroidal anti-inflammatory drugs (NSAIDs) was demonstrated to be an effective and convenient strategy for post-ERCP pancreatitis (PEP). Furthermore, several meta-analyses found that only 100mg indomethacin and diclofenac could effectively reduce PEP. Therefore, updated international clinical practice guidelines uniformly recommended administration of 100mg indomethacin or diclofenac in patients without contradictions. However, it was unclear which one of the two drug is more superior. A recent meta-analysis suggested 100mg rectal diclofenac was more efficacious than same-dose rectal indomethacin in PEP prevention (relative risk (RR) 0·59, 95% confidence intervals (CI) 0·40-0·89). Based on the results, we conducted a multicenter, double-blind, control trial to investigate whether 100mg diclofenac is superior than same-dose indomethacin. This trial planned to enroll 3612 patients in total. However, in the first interim analysis, PEP occurred in 53 patients (8.8%) of 600 patients allocated to diclofenac group and 37 patients (6.1%) of 604 patients allocated to indomethacin group (relative risk (RR) 1.44; 95% confidence interval (CI) 0.96-2.16, p=0.074). Thus, the trial was stopped according to the futility rule of conditional power. However, it was worth noticing that PEP tended to be higher in diclofenac group than that in indomethacin group. A sample size of 1204 was under power to draw the conclusion of significantly lower PEP rate in indomethacin group and thus a new trial with larger sample size of sufficient power is predicted to prove the superiority of indomethacin over diclofenac. Here we conducted a multicenter, randomized, double-blind trial to investigate whether 100mg indomethacin is superior to 100mg diclofenac in preventing PEP.


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Inclusion Criteria1

  • years old patients with native papilla who planned to undergo ERCP

Exclusion Criteria9

  • Previous biliary sphincterotomy and papillary large balloon dilation
  • Planned for placements of pancreatic duct stents (eg. pancreatic duct strictures, planned ampullectomy)
  • Allergy to NSAIDs
  • The administration of NSAIDs within 7 days
  • Not suitable for NSAIDs administration (gastrointestinal hemorrhage within 4 weeks, renal dysfunction \[Cr \>1.4mg/dl=120umol/l\]; presence of coagulopathy before the procedure)
  • Acute pancreatitis within 7 days before ERCP or acute pancreatitis with obvious Pancreatic edema and peripancreatic fluid collections
  • Hemodynamical instability
  • Pregnancy or lactation
  • Unable to give informed consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIndomethacin 100 MG

All patients without contraindications should receive 100mg rectal indomethacin within 30mins before ERCP procedure

DRUGDiclofenac 100mg

All patients without contraindications should receive 100mg rectal diclofenac within 30mins before ERCP procedure


Locations(20)

The first medical center, Chinese PLA General Hospital

Beijing, Beijing Municipality, China

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Department of Gastroenterology, Hongai Hospital

Xiamen, Fujian, China

Harbin Medical University Affiliated Fourth Hospital

Harbin, Heilongjiang, China

Zhaolei181220@163.Com

Harbin, Heilongjiang, China

Huaihe Hospital of Henan University

Kaifeng, Hennan, China

Renmin hospital of Wuhan University

Wuhan, Hubei, China

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China

Jilin Miniciple People'S Hospital

Jilin, Jilin, China

Qinghai University Affiliated Hospital

Xining, Qinghai, China

986 Hospital of Xijing Hospital

Xi'an, Shaanxi, China

Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China

Xijing Hospital of Digestive Diseases

Xi'an, Shaanxi, China

Shandong Provincial Third Hospital

Jinan, Shandong, China

The 960th Hospital of the PLA

Jinan, Shandong, China

Eastern Hepatobiliary Surgery Hospital

Shanghai, Shanghai Municipality, China

Affiliated Hangzhou First People's Hospital

Hangzhou, Zhejiang, China

the First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

the second Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07071441


Related Trials